HBsAg检测在慢性HBV患者管理中的作用

StephenW

Role of HBsAg Testing in the Management of Patients with Chronic HBV

    July 2019

    DOI: 10.1007/s11901-019-00484-y

    Tzu-Chan HongHung-Chih YangJia-Horng KaoJia-Horng Kao


Role of HBsAg Testing in the Management of Patients with Chronic HBV

Abstract
Purpose of Review HBsAg has been an important serological marker for the diagnosis of hepatitis B virus (HBV) infection. Recently, HBsAg quantification has been utilized to predict the disease activity and the response to antiviral treatment. This review aims to update the clinical utility of HBsAg quantification in the management of chronic hepatitis B (CHB). Recent Findings HBsAg level varies across different phases of the natural history of CHB, highest in the immune-tolerant phase and lowest in inactive carriers. HBsAg level is useful to stratify the risk of hepatocellular carcinoma in low-viremic patients. HBsAg level also helps predict the HBsAg loss in HBeAg-negative patients. Moreover, baseline level and on-treatment kinetics of HBsAg are associated with the treatment response to pegylated interferon and nucleos(t)ide analogs in both HBeAg-positive and HBeAg-negative patients. Finally, HBsAg level can serve as a therapeutic endpoint marker for evaluating novel curative agents against HBV infection. Summary HBsAg quantification can help guide the management of CHB.

StephenW

HBsAg检测在慢性HBV患者管理中的作用

    2019年7月

    DOI：10.1007 / s11901-019-00484-y

    Tzu-Chan HongHung-Chih YangJia-Horng KaoJia-Horng Kao


HBsAg检测在慢性HBV患者管理中的作用

抽象
回顾目的HBsAg是诊断乙型肝炎病毒（HBV）感染的重要血清学标志物。最近，HBsAg定量已被用于预测疾病活动和对抗病毒治疗的反应。本综述旨在更新HBsAg定量在慢性乙型肝炎（CHB）管理中的临床应用。最近的研究结果HBsAg水平在CHB自然史的不同阶段有所不同，在免疫耐受期最高，在非活动携带者中最低。 HBsAg水平可用于对低病毒血症患者的肝细胞癌风险进行分层。 HBsAg水平也有助于预测HBeAg阴性患者的HBsAg消失。此外，HBsAg的基线水平和治疗动力学与HBeAg阳性和HBeAg阴性患者对聚乙二醇化干扰素和核苷（t）ide类似物的治疗反应相关。最后，HBsAg水平可作为评估抗HBV感染的新型治疗剂的治疗终点标志物。总结HBsAg量化可以帮助指导CHB的管理。